Baudax Bio, Inc. announced that following recent shareholder approval of corporate actions related to its June 29, 2023 acquisition of TeraImmune, the Company is now poised to initiate clinical development of TI-168, the Company's next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors. The Company anticipates initiating its Phase 1/2a clinical study of TI-168 in Hemophilia A patients withFVIII inhibitors with a modest initial budget in First Quarter of 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.00718 USD | +2.57% |
|
-25.77% | -67.27% |
Jun. 17 | First Motion for Exclusivity Period Extension Filed by Baudax Bio, Inc. | CI |
Feb. 22 | Baudax Bio, Inc. Filed for Bankruptcy | CI |
1st Jan change | Capi. | |
---|---|---|
-67.27% | 377K | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- BXRXQ Stock
- News Baudax Bio, Inc.
- Baudax Bio, Inc. to Initiate TI-168 Clinical Development